Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hallard

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1997
Combinations of three or four HIV virostatics applied in short sequences which differ from each other by drug rotation. Preliminary results of the viral loads and CD4 numbersG Mathé, C Morette, M Hallard, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1996
Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy?G Mathé, U Colasanté, C Morette, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1994
Changes in the level of blood suppressor CD8+CD57+ lymphocytes, when HIV-1 p24 antigen reappears in the bloodG Mathé, C Morette, M Hallard, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 18, 1998
Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combinations with other HIV1 virostaticsG Mathé, K Triana, P Pontiggia, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1996
AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogueG Mathé, P Pontiggia, S Orbach-Arbouys, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1997
Combinations of three or four HIV virostatics applied in short sequences which differ from each other by drug rotation. Preliminary results of the viral loads and CD4 numbersG Mathé, C Morette, M Hallard, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1996
Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy?G Mathé, U Colasanté, C Morette, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1994
Changes in the level of blood suppressor CD8+CD57+ lymphocytes, when HIV-1 p24 antigen reappears in the bloodG Mathé, C Morette, M Hallard, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|December 18, 1998
Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combinations with other HIV1 virostaticsG Mathé, K Triana, P Pontiggia, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1996
AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogueG Mathé, P Pontiggia, S Orbach-Arbouys, et al.
Pageof 1